Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4422 - Dose distribution after tumor cavity injection in brain glioma patients

Date

10 Sep 2017

Session

Poster display session

Presenters

Ming Zhao

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

M. Zhao, X. Fu

Author affiliations

  • Department Of Neurosurgery, 1st Affiliated Hospital General Hospital of PLA, 100048 - Beijing/CN
More

Resources

Abstract 4422

Background

The local delivery of drug into brain has not been widely used because the unpredictable dose distribution and dose-toxicity effects that drug may carry. This study is to investigate the efficacy of drug delivery by intra-cerebral injection.

Methods

3 patients with deep-seated glioma underwent stereotactic biopsy and Ommaya reservoir implantation. Radioactive agent (131I-chTNT) was injected at a dose of (0.8mCi/cm3) through Ommaya reservoir. Patients were carefully observed and Post-operational PET was performed to reveal the body distribution of 131I and evaluate the distribution of drugs in whole body.

Results

After the intratumoral injection, most of the drug stayed in the brain tumor and decayed gradually for more than 4 weeks. Although the accumulation of 131I was also found in thyroid and urinary system as well as stomach and large intestine, it disappeared within 2 weeks while strong radioactivity was still seen in the brain tumor.

Conclusions

These images demonstrated excellent localization of the radiolabel in the tumor with little diffusion over time. Intra-tumoral injection of chemical or readioactive drugs is recommendable in the local treatment.

Clinical trial identification

Legal entity responsible for the study

Ming Zhao

Funding

Beijing Capital Developmental Fund (2014-2-5021)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.